Publications by authors named "Jia Jian Loh"

Article Synopsis
  • Hepatocellular carcinoma (HCC) has metabolic abnormalities that help cancer cells grow and resist treatment, making it vital to study new metabolic factors linked to these issues for better understanding and potential therapy advancements.
  • An analysis of cancer data revealed that a particular gene module correlates with advanced HCC disease and the maintenance of cancer stem cells, leading to the identification of 361 deregulated genes, with diacylglycerol kinase eta (DGKH) being a key player in promoting aggressive cancer traits.
  • DGKH's elevated levels in tumors make patients less responsive to treatments, and its action involves enhancing mTOR signaling through phosphatidic acid production; targeting DGKH may improve treatment outcomes
View Article and Find Full Text PDF

Cancer stemness is recognized as a key component of tumor development. Previously coined "cancer stem cells" (CSCs) and believed to be a rare population with rigid hierarchical organization, there is good evidence to suggest that these cells exhibit a plastic cellular state influenced by dynamic CSC-niche interplay. This revelation underscores the need to reevaluate the hallmarks of cancer stemness.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is an aggressive malignancy without effective therapeutic approaches. Here, we evaluate the tumor-intrinsic mechanisms that attenuate the efficacy of immune checkpoint inhibitor (ICI) that is observed in patients with advanced HCC who progress on first-line tyrosine kinase inhibitor (TKI) therapy. Upregulation of AXL observed in sorafenib- and lenvatinib-resistant HCCs is correlated with poor response towards TKI and ICI treatments.

View Article and Find Full Text PDF
Article Synopsis
  • Sorafenib is a key drug for treating advanced hepatocellular carcinoma (HCC) but shows reduced effectiveness due to ferroptosis suppression in resistant cases.
  • Long noncoding RNA URB1-AS1 is found to be highly expressed in sorafenib-resistant HCC and helps reduce ferroptosis, leading to worse outcomes for patients.
  • Targeting URB1-AS1 could potentially enhance the effectiveness of sorafenib treatment, offering a new strategy to combat resistance in HCC.
View Article and Find Full Text PDF

Targetable drivers governing 5-fluorouracil and cisplatin (5FU + CDDP) resistance remain elusive due to the paucity of physiologically and therapeutically relevant models. Here, we establish 5FU + CDDP resistant intestinal subtype GC patient-derived organoid lines. JAK/STAT signaling and its downstream, adenosine deaminases acting on RNA 1 (ADAR1), are shown to be concomitantly upregulated in the resistant lines.

View Article and Find Full Text PDF

The enrichment of cancer-associated fibroblast (CAFs) in a tumor microenvironment (TME) cultivates a pro-tumorigenic niche aberrant paracrine signaling and matrix remodeling. A favorable niche is critical to the maintenance of cancer stem cells (CSCs), a population of cells that are characterized by their enhanced ability to self-renew, metastasis, and develop therapy resistance. Mounting evidence illustrates the interplay between CAF and cancer cells expedites malignant progression.

View Article and Find Full Text PDF

The tumor microenvironment plays a critical role in maintaining the immature phenotype of tumor-initiating cells (TIC) to promote cancer. Hepatocellular carcinoma (HCC) is a unique disease in that it develops in the setting of fibrosis and cirrhosis. This pathologic state commonly shows an enrichment of stromal myofibroblasts, which constitute the bulk of the tumor microenvironment and contribute to disease progression.

View Article and Find Full Text PDF

CDK8 and its paralog, CDK19, collectively termed 'Mediator Kinase,' are cyclin-dependent kinases that have been implicated as key rheostats in cellular homeostasis and developmental programming. CDK8 and CDK19 are incorporated, in a mutually exclusive manner, as part of a 4-protein complex called the Mediator kinase module. This module reversibly associates with the Mediator, a 26 subunit protein complex that regulates RNA Polymerase II mediated gene expression.

View Article and Find Full Text PDF